Madrigal’s Rezdiffra Energizes MASH Space, Sets Bar for Future Therapies

With its FDA approval last week and first-to-market advantage, Madrigal Pharmaceuticals’ Rezdiffra will set the standard for other metabolic dysfunction-associated steatohepatitis candidates in development.